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Nanotechnology  increasingly  plays  a signiﬁcant  role  in vaccine  development.  As  vaccine  development
orientates  toward  less  immunogenic  “minimalist”  compositions,  formulations  that  boost  antigen  effec-
tiveness  are  increasingly  needed.  The  use  of  nanoparticles  in vaccine  formulations  allows  not  only
improved  antigen  stability  and immunogenicity,  but also targeted  delivery  and  slow  release.  A number
of  nanoparticle  vaccines  varying  in  composition,  size,  shape,  and  surface  properties  have  been  approved
for  human  use and  the  number  of  candidates  is increasing.  However,  challenges  remain  due  to  a lack
of  fundamental  understanding  regarding  the  in  vivo  behavior  of  nanoparticles,  which  can  operate  as
either  a delivery  system  to  enhance  antigen  processing  and/or  as  an  immunostimulant  adjuvant  to  acti-anoparticle
anotechnology
djuvant
anovaccinology
vate  or  enhance  immunity.  This  review  provides  a  broad  overview  of  recent  advances  in prophylactic
nanovaccinology.  Types  of  nanoparticles  used  are  outlined  and  their  interaction  with  immune  cells  and
the  biosystem  are  discussed.  Increased  knowledge  and  fundamental  understanding  of nanoparticle  mech-
anism  of  action  in  both  immunostimulatory  and  delivery  modes,  and better understanding  of  in  vivo
biodistribution  and  fate,  are  urgently  required,  and  will  accelerate  the  rational  design  of  nanoparticle-
containing  vaccines.
 201©
. Introduction
Vaccine development has a proud history as one of the most
uccessful public health interventions to date. Vaccine develop-
ent is historically based on Louis Pasteur’s “isolate, inactivate,
nject” paradigm. As vaccine development moves increasingly
o draw on modern concepts of rational design, the number of
andidate vaccines is increasing [1,2]. Most candidate vaccines rep-
esent “minimalist” compositions [3], which typically exhibit lower
mmunogenicity. Adjuvants and novel delivery systems that boost
mmunogenicity are increasingly needed as we move toward the
ra of modern vaccines.
Nanotechnology offers the opportunity to design nanoparticles
arying in composition, size, shape, and surface properties, for
pplication in the ﬁeld of medicine [4,5]. Nanoparticles, because of
heir size similarity to cellular components, can enter living cells
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using the cellular endocytosis mechanism, in particular pinocy-
tosis [6]. These cutting-edge innovations underpinned a market
worth US $6.8 billion in 2006 [7] and predicted to reach US $160
billion by 2015 [8]. Indeed, nanoparticles are revolutionizing the
diagnosis of diseases as well as the delivery of biologically-active
compounds for disease prevention and treatment. The emergence
of virus-like particles (VLPs) and the resurgence of nanoparticles,
such as quantum dots and magnetic nanoparticles, marks a conver-
gence of protein biotechnology with inorganic nanotechnology that
promises an era of signiﬁcant progress for nanomedicine [9,10]. A
number of approved nano-sized vaccine and drug delivery systems
highlight the revolution in disease prevention and treatment that
is occurring [4,11–13].
The  use of nanotechnology in vaccinology, in particular, has
been increasing exponentially in the past decade (Fig. 1), lead-
ing to the birth of “nanovaccinology” [3]. In both prophylactic
and therapeutic approaches, nanoparticles are used as either
a delivery system to enhance antigen processing and/or as an
immunostimulant adjuvant to activate or enhance immunity. Ther-
apeutic nanovaccinology is mostly applied for cancer treatment
[14–16], and is increasingly explored to treat other diseases or
Open access under CC BY-NC-ND license.conditions, such as Alzheimer’s [17], hypertension [9], and nico-
tine addiction [11]. Prophylactic nanovaccinology, on the other
hand, has been applied for the prevention of different diseases.
A number of prophylactic nanovaccines have been approved
 license.
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nd  vaccin*” from Web  of Science (http://apps.webofknowledge.com/; results for
 search conducted on 29 July 2013).
or human use and more are in clinical or pre-clinical trials
13,18–20].
In this review, we provide an overview of recent advances in
he broad area of nanovaccinology, but limit our review only to
rophylactic vaccines. We  ﬁrst survey advances in the types of
anoparticles, which are deﬁned as any particulate material with
ize 1–1000 nm [21], used for prophylactic vaccine design (Fig. 2).
e then discuss the interaction of nanoparticles with the antigen
f interest, differentiating the role of the nanoparticle as either
elivery system and/or immunostimulant adjuvant. The interac-
ion of nanoparticles with immune cells and the biosystem are
lso discussed to provide understanding of antigen and nanopar-
icle processing in vivo, as well as clearance. This latter aspect is
f particular timeliness considering that there is limited history of
afe use for non-VLP nanoparticles in humans. We  then conclude
ith remarks about the further potential and future prospects for
rophylactic nanovaccinology.
.  Types of nanoparticles
.1.  Polymeric nanoparticles
A  great variety of synthetic polymers are used to prepare
anoparticles, such as poly(d,l-lactide-co-glycolide) (PLG) [22–24],
oly(d,l-lactic-coglycolic acid)(PLGA) [22,25–30], poly(g-glutamic
cid) (g-PGA) [31,32], poly(ethylene glycol) (PEG) [24], and
olystyrene [33,34]. PLG and PLGA nanoparticles have been the
ost extensively investigated due to their excellent biocompati-
ility and biodegradability [35,36]. These polymeric nanoparticles
ntrap antigen for delivery to certain cells or sustain antigen release
y virtue of their slow biodegradation rate [27–29,31,36]. PLGA has
een used to carry antigen derived from various pathogens includ-
ng Plasmodium vivax with mono-phosphoryl lipid A as adjuvant
Fig. 2. The size range of nanopartic (2014) 327– 337
[37],  hepatitis B virus (HBV) [22], Bacillus anthracis [29], and model
antigens such as ovalbumin and tetanus toxoid [26,27]. g-PGA
nanoparticles are comprised of amphiphilic poly(amino acid)s,
which self-assemble into nano-micelles with a hydrophilic outer
shell and a hydrophobic inner core [31,32]. g-PGA nanoparticles
are generally used to encapsulate hydrophobic antigen [31,32].
Polystyrene nanoparticles can conjugate to a variety of antigens
as they can be surface-modiﬁed with various functional groups
[33,38].
Natural polymers based on polysaccharide have also been
used to prepare nanoparticle adjuvants, such as pullulan [39,40],
alginate [41], inulin [42,43], and chitosan [44–49]. In particular,
chitosan-based nanoparticles have been widely studied due to their
biocompatibility, biodegradability, nontoxic nature and their abil-
ity to be easily modiﬁed into desired shapes and sizes [31,50,51].
These nanoparticles have been used in the preparation of various
vaccines including HBV vaccines [49], Newcastle disease vaccines
[48], and DNA vaccines [44,46,47]. Inulin, a well-known activator of
complement via the alternative pathway [52], is also a potent adju-
vant. Nanoparticle adjuvants derived from inulin, such as AdvaxTM,
have shown enhancement of immune response in vaccines against
various viruses including inﬂuenza [42] and hepatitis B [43].
Polymers,  such as Poly(L-lactic acid) (PLA), PLGA, PEG, and
natural polymers such as polysaccharides [41,53–55], have also
been used to synthesize hydrogel nanoparticles, which are a type
of nano-sized hydrophilic three-dimensional polymer network.
Nanogels have favorable properties including ﬂexible mesh size,
large surface area for multivalent conjugation, high water content,
and high loading capacity for antigens [55,56]. Chitosan nanogels
have been widely used in antigen delivery, such as Clostridium
botulinum type-A neurotoxin subunit antigen Hc for an adjuvant-
free intranasal vaccine [57], and recombinant NcPDI antigen for
Neospora caninum vaccination [58].
2.2. Inorganic nanoparticles
Many  inorganic nanoparticles have been studied for their
use in vaccines. Although these nanoparticles are mostly non-
biodegradable, the advantage of them lies in their rigid structure
and controllable synthesis [33]. Gold nanoparticles (AuNPs) are
used in vaccine delivery [35], as they can be easily fabricated into
different shapes (spherical, rod, cubic, etc.) [59] with a size range of
2–150 nm [60], and can be surface-modiﬁed with carbohydrates
[61]. Gold nanorods have been used as a carrier for an antigen
derived from respiratory syncytial virus by conjugating the antigen
to the surface [62]. Other types of gold nanoparticles have been used
as carriers for antigens derived from other viruses such as inﬂuenza
[63] and foot-and-mouth disease [64], or as a DNA vaccine adjuvant
for human immunodeﬁciency virus (HIV) [65].Carbon nanoparticles are another commonly-studied compo-
sition for drug and vaccine delivery [60]. They are known for
their good biocompatibility and can be synthesized into a vari-
ety of nanotubes and mesoporous spheres [66–68]. The diameter
les used in nanovaccinology.
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f carbon nanotubes (CNTs) used as carriers is generally 0.8–2 nm
ith a length of 100–1000 nm [69,70], while the size of mesoporous
arbon spheres is around 500 nm [67]. Multiple copies of protein
nd peptide antigens can be conjugated on to CNTs for delivery and
ave enhanced the level of IgG response [67,69–71]. Mesoporous
arbon nanoparticles have been studied for application as an oral
accine adjuvant [67].
One  of the most promising inorganic materials for nanovaccinol-
gy and delivery system design is silica. Silica-based nanoparticles
SiNPs) are biocompatible and have excellent properties as
anocarriers for various applications, such as selective tumor
argeting [72], real-time multimodal imaging [73], and vaccine
elivery. The SiNPs can be prepared with tunable structural param-
ters. By controlling the sol–gel chemistry, the particle size and
hape of SiNPs can be adjusted to selectively alter their inter-
ction with cells [74]. The abundant surface silanol groups are
eneﬁcial for further modiﬁcation to introduce additional function-
lity, such as cell recognition, absorption of speciﬁc biomolecules,
mprovement of interaction with cells, and enhancement of cellu-
ar uptake [75–78]. In addition, porous SiNPs such as mesoporous
ilica nanoparticles (MSNs) and hollow SiNPs can be prepared by
emplating methods, which can be applied as a multifunctional
latform to simultaneously deliver cargo molecules with various
olecular weights [74]. MSNs with sizes in the range of 50–200 nm
ave been studied as both nano-carriers and adjuvants for delivery
f effective antigens [79–81], such as those derived from porcine
ircovirus [82] and HIV [83]. MSNs can be used to control the release
f antigens by controlling the shape, pore size and surface func-
ionalization [79,84]. Compared to solid SiNPs, MSNs have higher
oading capacity for their larger speciﬁc surface area, and better
erformance in delivery and controlled release due to the tun-
ble hollow and mesoporous structure. In addition, MSNs can be
egraded which can then be excreted in the urine [85–87]. With
hese properties, MSNs show potential to become high-efﬁciency,
ontrolled-release nano-carriers in future vaccine formulations.
Calcium  phosphate nanoparticles can be created by mixing cal-
ium chloride, dibasic sodium phosphate and sodium citrate under
peciﬁc conditions [88,89]. They are non-toxic and can be formed
nto a size of 50–100 nm [90]. These nanoparticles are useful adju-
ants for DNA vaccines and mucosal immunity [79,88–90], and
how excellent biocompatibility.
.3.  Liposomes
Liposomes are formed by biodegradable and nontoxic phos-
holipids. Liposomes can encapsulate antigen within the core
or delivery [91] and incorporate viral envelope glycoproteins to
orm virosomes [92,93] including for inﬂuenza [94]. Combination
f 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) modiﬁed
ationic liposome and a cationic polymer (usually protamine) con-
ensed DNA are called liposome-polycation-DNA nanoparticles
LPD), a commonly used adjuvant delivery system in DNA vaccine
tudies [95,96]. The components of LPD spontaneously rearrange
nto a nano-structure around 150 nm in size with condensed
NA located inside the liposome [96]. Liposomes modiﬁed with
aleimide can be synthesized into interbilayer-crosslinked multi-
amellar vesicles (ICMVs) by cation driven fusion and crosslinking
97] enabling slowed release of entrapped antigen. A number of
iposome systems have been established and approved for human
se, such as Inﬂexal® V and Epaxal®, which have been discussed in
ther reviews [91,98]..4.  Immunostimulating complex (ISCOM)
ISCOMs are cage like particles about 40 nm large in size, made
f the saponin adjuvant Quil A, cholesterol, phospholipids, and (2014) 327– 337 329
protein  antigen [35,92,99–101]. These spherical particles can trap
the antigen by apolar interactions [35]. ISCOMATRIX comprises
ISCOMs without antigen [35,92,100,102]. ISCOMATRIX can be
mixed with antigen, enabling a more ﬂexible application than is
possible for ISCOMs, by removing the limitation of hydrophobic
antigens [35]. Various antigens have been used to form ISCOMs,
including antigens derived from inﬂuenza [103,104], herpes
simplex virus [105], HIV [106], and Newcastle disease [99].
2.5.  Virus-like particles
Virus-like  particles (VLP) are self-assembling nanoparticles,
lacking infectious nucleic acid, formed by self-assembly of biocom-
patible capsid proteins [107,108]. VLPs are the ideal nanovaccine
system as they harness the power of evolved viral structure, which
is naturally optimized for interaction with the immune system, but
avoid the infectious components. VLPs take the good aspects of
viruses and avoid the bad. The naturally-optimized nanoparticle
size and repetitive structural order means that VLPs induce potent
immune responses, even in the absence of adjuvant [109]. VLP
based vaccines are the ﬁrst nanoparticle class to reach market – the
ﬁrst VLP vaccine for hepatitis B virus was  commercialized in 1986
[110] – and have become widely administered in healthy popu-
lations. In nanovaccinology, VLP nanoparticles have the strongest
evidence base for safe use in healthy humans. Newer VLP vaccines
for human papillomavirus [111] and hepatitis E [112] have been
approved for use in humans in 2006 and 2011, respectively.
VLPs can be derived from a variety of viruses (Fig. 3) [107],
with sizes ranging from 20 nm to 800 nm [13,113], and can be
manufactured with a variety of process technologies [114]. The
historical approach to VLP manufacture involves an in vivo route,
where the assembly of capsid proteins into VLPs occurs inside
the expression host. The assembled particle is then puriﬁed away
from adherent and encapsulated contaminants. In some cases it
becomes necessary to disassemble and then re-assemble the VLP
to improve quality [114]; recently-approved VLP vaccines typi-
cally include some aspect of extracellular assembly within the
processing regime. An emerging approach for VLP assembly is
through cell-free in vitro processing [115–119]. This approach
inverts the traditional assemble-then-purify paradigm; large-scale
puriﬁcation of the VLP building blocks from contaminants occurs
ﬁrst, then these are assembled in vitro, avoiding the need to disas-
semble VLP structures after assembly in a cell. Further review of VLP
manufacturing approaches is available elsewhere [13,19,120,121].
VLPs  commercialized to date are based on self-assembly of pro-
teins derived from the target virus. However, VLPs can also act as a
delivery platform where a target antigen from a virus unrelated to
the VLP used is modularized on the surface of a VLP [20,122–125].
These modular VLPs exploit known beneﬁts of VLPs (optimized
particle size and molecular structure) to target disease in an engi-
neered fashion. With many VLP vaccines currently in clinical or
pre-clinical trials [13,19], an increase in the number of approved
VLP-based vaccines can be expected.
2.6. Self-assembled proteins
Recognizing  the power of the VLP approach, self-assembling
systems  that attempt to drive higher levels of protein quaternary
structuring have emerged for the preparation of nanoparticle-
based vaccines. Ferritin is a protein that can self-assemble into
nearly-spherical 10 nm structure [126]. By genetically fusing
inﬂuenza virus haemagglutinin (HA) to ferritin, the recombined
protein spontaneously assembled into an octahedrally-symmetric
particle and reformed 8 trimeric HA spikes [126] to give a higher
immune response than trivalent inactivated inﬂuenza vaccine,
which typically is processed to destroy rather than build viral
330 L.  Zhao et al. / Vaccine 32 (2014) 327– 337
Fig. 3. Structure of virus-like particles. Virus-like particles can be derived from a variety of viruses. HEV, hepatitis E virus; HPV, human papillomavirus 16; SIV-HIV, hybrid
VLP  between simian immunodeﬁciency virus gag and human immunodeﬁciency virus env; HCV, hepatitis C virus; BTV, bluetongue virus.
Reprinted  from Trends in Microbiology, Vol. 11, Issue 8, Rob Noad and Polly Roy, Virus-like particles as immunogens, Pages 438–444, Copyright (2003), with permission from
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tructure. This example highlights the importance of driving
igher-order molecular structure in modern vaccines. The major
ault protein (MVP) is another kind of self-assembling protein.
inety-six units of MVP  can self-assemble into a barrel-shaped
ault nanoparticle, with a size of approximately 40 nm wide and
0 nm long [127]. Antigens that are genetically fused with a mini-
al interaction domain can be packaged inside vault nanoparticles
y self-assembling process when mixed with MVPs [127]. Vault
anoparticles have been used to encapsulate the major outer mem-
rane protein of Chlamydia muridarum for studies of mucosal
mmunity [127].2.7. Emulsions
Another type of nanoparticles used as adjuvants in vaccines
delivery is nano-sized emulsions [100,128,129]. These nanopar-
ticles can exist as oil-in-water or water-in-oil forms, where the
droplet size can vary from 50 nm to 600 nm [128]. Emulsions can
carry antigens inside their core for efﬁcient vaccine delivery [128]
or can also be simply mixed with the antigen. One commonly-
used emulsion is MF59TM, an oil-in-water emulsion which has been
licensed as a safe and potent vaccine adjuvant in over 20 countries
[35,130]. It has been widely studied for use in inﬂuenza vaccines
L. Zhao et al. / Vaccine 32 (2014) 327– 337 331
Fig. 4. Schematic representation of PEG (white) chemically conjugated to DAMP4 protein (dark blue) being introduced to a solution containing pre-formed nanoemulsion
oil core (light yellow) stabilized by AM1  peptide (red), in aqueous buffer (light blue background). DAMP4 protein, which is chemically similar to AM1  peptide, is able to
integrate into the oil-water interface formed between the core and the aqueous bulk. Prior conjugation of PEG to DAMP4 leads to its functional display at the interface through
non-covalent molecular self-assembly. (For interpretation of the references to color in ﬁgure legend, the reader is referred to the web  version of the article.)
Reprinted from Small, http://dx.doi.org/10.1002/smll.201300078, B.J. Zeng, Y.P. Chuan, B. O’Sullivan, I. Caminschi, M.H. Lahoud, R. Thomas, A.P.J. Middelberg, Receptor-Speciﬁc
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130–132]. Another is MontanideTM, a large family of both oil-in-
ater and water-in-oil emulsions, including ISA 50 V, 51, 201, 206
nd 720 [35,133]. Montanide ISA 51 and 720 have been used in
alaria vaccines [134,135], Montanide ISA 201 and 206 have been
sed in foot-and-mouth disease vaccines [136].
Recently, a tailorable nano-sized emulsion (TNE) platform tech-
ology has been developed using non-covalent click self-assembly
or antigen and drug delivery [137,138]. An oil-in-water nanoemul-
ion is formed using designed biosurfactant peptides and proteins.
sing a self-assembling peptide-protein system, immune-evading
EG and a receptor-speciﬁc antibody can be arrayed in a selectively
roportioned fashion on the aqueous interface of a nano-sized oil-
n-water emulsion (Fig. 4). Targeted delivery of protein antigen to
endritic cells was achieved [138]. This work demonstrates a new
nd simple way to make biocompatible designer nanoemulsions
sing non-covalent click self-assembly by sequential top-down
eagent addition.
.  Nanoparticle interaction with antigen
Vaccine formulations comprising nanoparticles and antigens
an be classiﬁed by nanoparticle action into those based on delivery
ystem or immune potentiator approaches. As a delivery system,
anoparticles can deliver antigen to the cells of the immune system,
.e. the antigen and nanoparticle are co-ingested by the immune cell,
r act as a transient delivery system, i.e. protect the antigen and
hen release it at the target location [79]. For nanoparticles to func-
ion as a delivery system, association of antigen and nanoparticle isn Non-Covalent Click Self-Assembly, Copyright (2003), with permission from John
typically necessary. For immune potentiator approaches, nanopar-
ticles activate certain immune pathways which might then enhance
antigen processing and improve immunogenicity.
Hard material nanoparticles, such as those based on silica, gold,
and calcium phosphate, have predominantly been examined for
use as a delivery system [139] and have thus been engineered
to promote antigen attachment. Attachment of antigen has been
achieved through simple physical adsorption or more complex
methods, such as chemical conjugation or encapsulation (Fig. 5).
Adsorption of antigen onto a nanoparticle is generally based simply
on charge or hydrophobic interaction [79,140,141]. Therefore, the
interaction between nanoparticle and antigen is relatively weak,
which may  lead to rapid disassociation of antigen and nanopar-
ticle in vivo. Encapsulation and chemical conjugation provide for
stronger interaction between nanoparticle and antigen. In encap-
sulation, antigens are mixed with nanoparticle precursors during
synthesis, resulting in encapsulation of antigen when the precur-
sors particulate into a nanoparticle [88]. Antigen is released only
when the nanoparticle has been decomposed in vivo or inside
the cell. On the other hand, for chemical conjugation, antigen is
chemically cross-linked to the surface of a nanoparticle [142]. Anti-
gen is taken up by the cell together with the nanoparticle and
is then released inside the cell. In soft matter nanoparticle deliv-
ery system, such as those based on VLPs, ISCOM, ISCOMATRIXTM,
or liposomes, attachment of antigen is achieved through chemi-
cal conjugation, adsorption, encapsulation, or fusion at DNA level
[91,94,101,102,123–125].
For nanoparticles to act as an immune potentiator, attach-
ment or interaction between the nanoparticle and antigen is not
332 L.  Zhao et al. / Vaccine 32 (2014) 327– 337
Fig. 5. Interaction of nanoparticle with antigen of interest. Formulation of nanoparticle and antigen of interest can be through attachment (e.g. conjugation, encapsulation,
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ecessary, and may  be undesirable in cases where modiﬁcation
f antigenic structure occurs at the nanoparticle interface. Soft-
atter nanoparticles, such as emulsion-based adjuvants MF59TM
nd AS03TM, have been shown to adjuvant a target antigen even
hen they are injected independently of, and before, the antigen
143,144]. Building on this idea, formulation of immune potentia-
or nanoparticles with a target antigen could be possible through
imple mixing of nanoparticle and adjuvant, shortly prior to injec-
ion, with minimal association between nanoparticle and antigen
eeded. This approach has only recently been investigated for
ard-material nanoparticle adjuvants, with results suggesting that
anoparticles may  act as a size-dependent immune potentiator
djuvant even when not conjugated to the antigen [145]. This new
nding is consistent with a number of other studies that have
emonstrated induction of inﬂammatory immune responses after
njection of hard material nanoparticles alone and without antigen
146,147]. Further studies into the use of nanoparticles as immune-
otentiating adjuvants are clearly needed. As the interaction of
anoparticles with the immune system becomes more fully under-
tood, we expect their impact to be broadened.
. Nanoparticle interactions with antigen presenting cells
Incorporating  antigenic components into nanoparticles has
ttracted extensive interest with a focus on how to deliver antigen
ore efﬁciently to antigen presenting cells (APCs) and subse-
uently induce their maturation and cross presentation of antigen
or activation of a potent immune response [148–152]. As special-
zed APCs which efﬁciently uptake and process antigen, dendritic
ells (DCs) and macrophages are often targeted in vaccine design.
ood understanding of DC and macrophage uptake mechanisms
nd interactions of NPs with these cells is therefore very important
or developing efﬁcacious nanoparticle vaccines [153–155]. Stud-
es have reported that size, charge and shape of nanoparticles play
igniﬁcant roles in antigen uptake.
Generally, nanoparticles having a comparable size to pathogens
an be easily recognized and are consequently taken up efﬁ-
iently by APCs for induction of immune response [156–162].
Cs preferentially uptake virus-sized particles (20–200 nm)  while
acrophages preferentially uptake larger particles (0.5–5 m)
156]. In an in vitro study using polystyrene particles ranging from
.04 m to 15 m,  the optimum size for DC uptake was  found to besmaller  than 500 nm [163]. Similarly, 300 nm sized PLGA particles
also showed higher internalization and activation of DCs in com-
parison to 17, 7 and 1 m particles [164]. Higher uptake of smaller
PLA particles (200–600 nm)  in comparison to larger ones (2–8 m)
has also been reported for uptake by macrophages [165]. Differ-
ent studies however, show discrepancies in optimum nanoparticle
vaccine size. Amphiphilic poly(amino acid) (PAA) nanoparticles of
30 nm were shown to have a lower DC uptake than that of 200 nm
nanoparticles [166]. Polyacrylamide hydrogel particles of 35 nm
and 3.5 m in size showed no difference in macrophages uptake
[167]. These discrepancies may  be related to the intrinsic differ-
ences in the material properties, with each material having an
optimum size for induction of potent immune response [168].
In  addition to particle size, surface charge also plays a signiﬁcant
role in the activation of immune response. Cationic nanoparticles
have been shown to induce higher APC uptake due to electrostatic
interactions with anionic cell membranes [163]. In vitro stud-
ies suggested that a cationic surface could signiﬁcantly enhance
the uptake of polystyrene particles of micron size (∼1 m)  by
macrophages and DCs in comparison with a neutral or negative sur-
face [163,169,170], but not for the smaller nanoparticles (100 nm)
[163]. However, other in vivo studies revealed that either positively
[171] or negatively charged [172] liposomes could act as efﬁcient
adjuvants to induce cell-mediated immune response. Furthermore,
due to their electrostatic interaction with anionic cell membranes,
cationic particles are more likely to induce hemolysis and platelet
aggregation than neutral or anionic particles [173].
Particle shape plays an equally important role in the interaction
between nanoparticles and APCs. For big particles (>1 m),  parti-
cle shape plays a dominant role in phagocytosis by macrophages as
the uptake of particles is strongly dependent on the local shape at
the interface between particles and APCs [174]. Worm-like parti-
cles with high aspect ratios (>20) exhibited negligible phagocytosis
compared to spherical particles [175]. On the other hand, spherical
gold nanoparticles (AuNPs) (40 nm)  were more effective in induc-
ing antibody response than other shapes (cube and rod) or the
20 nm-sized AuNPs, even though the rods (40 nm × 10 nm) were
more efﬁcient in APC uptake than the spherical and cubic AuNPs
[59].
A number of studies also reported the effect of hydrophobicity,
showing higher immune response for hydrophobic particles than
hydrophilic ones [176,177]. A number of other factors such as
cine 32
s
c
n
5
t
b
i
s
t
c
e
i
c
E
o
i
n
L
r
a
f
s
a
s
T
n
t
(
a
i
o
t
m
t
C
b
s
r
h
b
o
m
o
t
a
s
F
n
f
n
w
u
(
i
c
e
iL. Zhao et al. / Vac
urface modiﬁcation (pegylation, targeting ligands) and vaccine
argo [45] have been shown to affect the interaction between
anoparticles and APCs as well.
. Nanoparticle-biosystem interactions
Designing safe and efﬁcacious nanoparticle vaccines requires a
horough understanding of the interaction of nanoparticles with
iological systems which then determines the fate of nanoparticles
n vivo. Physicochemical properties of nanoparticles including size,
hape, surface charge, and hydrophobicity inﬂuence the interac-
ion of nanoparticles with plasma proteins [178,179] and immune
ells [176]. These interactions as well as morphology of vascular
ndothelium play an important role in distribution of nanoparticles
n various organs and tissues of the body.
The lymph node (LN) is a target organ for vaccine delivery since
ells of the immune system, in particular B and T cells, reside there.
nsuring delivery of antigen to LNs, by direct drainage [180,181]
r by migration of well-armed peripheral APCs [182], for optimum
nduction of immune response is therefore an important aspect of
anoparticle vaccine design. Distribution of nanoparticles to the
N is mainly affected by size [183,184]. Nanoparticles with a size
ange of 10–100 nm can penetrate the extracellular matrix easily
nd travel to the LNs where they are taken up by resident DCs
or activation of immune response [184–187]. Particles of larger
ize (>100 nm)  linger at the administration point [181,186,188]
nd are subsequently scavenged by local APCs [181,187,189], while
maller particles (<10 nm)  drain to the blood capillaries [184,189].
he route of administration and biological environment to which
anoparticles are exposed could also affect the draining of nanopar-
icles to the LN. It was reported that small PEG coated liposomes
80–90 nm)  were signiﬁcantly present in larger amounts in LNs
fter subcutaneous administration as compared to intravenous and
ntraperitoneal administration [190].
In addition to targeting lymphatic organ for efﬁcient activation
f immune response, design of nanoparticle vaccines also needs
o consider nanoparticle clearance from the body. Adverse effects
ay occur when nanoparticles are not degraded or excreted from
he body and hence, accumulate in different organs and tissues.
learance of nanoparticles could be achieved through degradation
y the immune system or by renal or biliary clearance.
Renal clearance through kidneys can excrete nanoparticles
maller than 8 nm [191,192]. Surface charge also plays an important
ole in determining renal clearance of nanoparticles. Few reports
ave suggested that for appropriate identically sized particles,
ased on surface charge, ease of renal clearance follows the order
f positively-charged < neutral < negatively charged [193,194]. This
ay  be attributed to the presence of negatively-charged membrane
f glomerular capillary [195].
On the other hand, biliary clearance through liver allows excre-
ion of nanoparticles larger than 200 nm [191,196]. Surface charge
lso plays role in biliary clearance with increase in surface charges
howing increased distribution of nanoparticles in the liver [197].
urthermore, a study reported shape dependent distribution of
anoparticles where short rod nanoparticles were predominantly
ound in liver, while long rods were found in spleen. Short rod
anoparticles were excreted at a faster rate than longer ones [198].
In order to aid understanding of interaction of nanoparticles
ith immune cells and the biosystem, many different in vivo molec-
lar imaging techniques including magnetic resonance imaging
MRI), positron emission tomography (PET), ﬂuorescence imag-
ng, single photon emission computed tomography (SPECT), X-ray
omputed tomography (CT) and ultrasound imaging could be
mployed. Owing to its excellent soft tissue contrast and non-
nvasive nature, MRI  imaging is extensively used for obtaining (2014) 327– 337 333
three-dimensional images in vivo. Superparamagnetic iron oxide
nanoparticles (SPION) have been extensively used as contrast
agents for morphological imaging [199,200]. PET usually employs
an imaging device (PET scanner) and a radiotracer that is usually
intravenously injected into the bloodstream. Due to high sensitivity
of this technique, it is used to study the biodistribution of particles
of interest. The only disadvantage of this technique is relatively
low spatial resolution as compared to other techniques. PET imag-
ing of 64Cu radiolabelled shell-crosslinked nanoparticles has been
demonstrated [201]. Fluorescence imaging facilitates imaging of
nanoparticles using ﬂuorescent tags. Dye-doped silica nanoparti-
cles as contrast imaging agents for in vivo ﬂuorescence imaging in
small animals have been reported [202].
Nowadays, more attention is being paid to synergize two or
more imaging techniques that complement each other and provide
an opportunity to overcome shortcomings of individual techniques
in terms of resolution or sensitivity. For instance, simultaneous
PET-MRI imaging is a new emerging hybrid imaging system that
combines the morphological imaging component of MRI with the
functional imaging component of PET [203]. Multifunctionality of
nanoparticles can be utilized for such hyphenated imaging.
6.  Concluding remark
Nanoparticle-containing vaccines have attracted tremendous
interest in recent years, and a wide variety of nanoparticles have
been developed and employed as delivery vehicles or immune
potentiators, allowing not only improvement of antigen stability
and the enhancement of antigen processing and immunogenicity,
but also the targeted delivery and slow release of antigens. In addi-
tion, nanoparticles have been increasingly used to deliver not only
antigen of interest but also co-adjuvant, such as poly(I:C), CpG and
MPL  [188,204]. However, the application of nanoparticles in vac-
cine delivery as well as in drug delivery is still at an early stage
of development. A number of challenges remain, including difﬁ-
culty in reproducibly synthesizing non-aggregated nanoparticles
having consistent and desirable properties, a lack of fundamen-
tal understanding of how the physical properties of nanoparticles
affect their biodistribution and targeting, and how these proper-
ties inﬂuence their interactions with the biological system at all
levels from cell through tissue and to whole body. Therefore, ratio-
nal design in combination with the reproducible production of
nanoparticles with desirable properties, functionalities and efﬁ-
cacy becomes increasingly important, and it is anticipated that
the adoption of new technologies, for example microﬂuidics, for
the controlled synthesis of nanoparticles will accelerate the devel-
opment of suitable nanoparticles for pharmaceutical applications
[205]. Furthermore, by integrating some other attractive proper-
ties, such as slow release, targeting and alternative administration
methods and delivery pathways, novel vaccine systems for unmet
needs including single-dose and needle-free delivery will become
practical in the near future.
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